OR WAIT 15 SECS
February 07, 2021
Anat Loewenstein, MD, provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD.
February 05, 2021
Joshua Mali, MD, discusses the three major risk factors for developing age-related macular degeneration (AMD).
February 03, 2021
Ian C. Han, MD, dives into the basics of age-related macular degeneration (AMD) and what patients need to know.
January 28, 2021
Rishi P. Singh, MD, highlights various treatment options available for the management of patients with age-related macular degeneration, as well as the status of potential therapies.
August 14, 2020
Subretinal transplantation of human embryonic stem cells (hESC)-derived retinal pigment epithelial (RPE) cells in patients with AMD and geographic atrophy (GA) appears well tolerated, according to date presented during ARVO 2020.
August 13, 2020
The number of patients with retinal diseases is steadily increasing in the United States, according to a retrospective study presented during ARVO 2020.
August 01, 2020
Why progression to advanced disease may have a more dramatic impact on patients with neovascular AMD compared with those with central geographic atrophy.
July 27, 2020
Carl Danzig, MD, presented results of phase 2 Stairway Trial during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.
July 22, 2020
The study authors hypothesized that patients poorly responding to ranibizumab may have resulted from tachyphylaxis or tolerance to the drug and regarding the nonresponders, they speculated that VEGF-A may not have been the main cause of the neovascular growth.
July 17, 2020
An in-office intravitreal therapy delivering a gene for aflibercept expression continues to demonstrate encouraging safety, tolerability, and efficacy in a phase 1 study of patients with neovascular age-related macular degeneration who require frequent injections to control their disease.
